

<u>Short Name</u>	<u>Comments</u>	<u>Type</u>	<u>Investigator</u>	<u>Contact</u>
Glioma Registry	Glioma Data Registry for Research	Registry	<b>SHORE:</b> Dr. Todd Vitaz	<b>James Nelson</b> james.nelson@spectrumhealth.org 616.267.8277
2015-175	<b>NMTRC012 - PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy- A Pilot Study Using Molecular Guided Therapy with Induction Chemotherapy followed by maintenance with DFMO for Subjects with Newly Diagnosed High-Risk Neuroblastoma</b>	Treatment	<b>SHORE:</b> Dr. Deanna Mitchell	<b>Sarah Vos</b> sarah.vos@helendevoschildrens.org 616.486.2064 <b>Julie Steinbrecher</b> julie.steinbrecher@helendevoschildrens.org 616.267.1163
2016-258	<b>HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors. Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to Either Single-Cycle or to Three Sequential Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue</b>	Treatment	<b>SHORE:</b> Dr. Albert Cornelius	<b>Sarah Vos</b> sarah.vos@helendevoschildrens.org 616.486.2064 <b>Julie Steinbrecher</b> julie.steinbrecher@helendevoschildrens.org 616.267.1163 <b>Laura Paulsen</b> laura.paulsen@spectrumhealth.org 616.486.6125
NMTRC 014-NMTT	<b>NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)</b>	Treatment	<b>SHORE:</b> Dr. Deanna Mitchell	<b>Sarah Vos</b> sarah.vos@helendevoschildrens.org 616.486.2064 <b>Julie Steinbrecher</b> julie.steinbrecher@helendevoschildrens.org 616.267.1163

	<b>A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children with Recurrent/progressive Medulloblastoma</b>	Treatment	<b>SHORE:</b> Dr. Rebecca Loret de Mola	<p><b>Sarah Vos</b> sarah.vos@helendevoschildrens.org 616.486.2064</p> <p><b>Julie Steinbrecher</b> julie.steinbrecher@helendevoschildrens.org 616.267.1163</p> <p><b>Laura Paulsen</b> laura.paulsen@spectrumhealth.org 616.486.6125</p>
<b>NRG BN003</b>	<b>Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>
<b>A071401</b>	<b>A Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>
<b>ACNS1721</b>	<b>A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>
<b>ACNS1723</b>	<b>Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients with Newly Diagnosed High Grade Glioma</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>
<b>A071701</b>	<b>Genomically-guided Treatment Trial in Brain Metastases</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>
<b>URCC 19085</b>	<b>A Phase II Clinical trial with Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-induced Peripheral Neuropathy</b>	Treatment	<b>CRCWM</b> Physician Investigators	<p>CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a></p>

---

**ACNS1422****A Phase II Study of Reduced Therapy for Newly Diagnosed  
Average-risk WNT-Driven Medulloblastoma Patients**

Treatment

**CRCWM**  
Physician  
InvestigatorsCRCWM  
(616) 391-1230  
[www.crcwm.org](http://www.crcwm.org)